Independent Research
IBRX Analysis
5 pieces of research on ImmunityBio, Inc.. We find the signal management buried in the earnings call.
ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears
ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its Anktiva imm…
Read analysis →ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
The FDA issued an enforcement action calling ImmunityBio's promotional claims for ANKTIVA "misleading," directly undermining the commercial adoption narrative b…
Read analysis →ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling
ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk event for …
Read analysis →ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over m…
Read analysis →ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
ImmunityBio confirmed statistical power in its pivotal ANKTIVA bladder cancer trial but faces an offsetting FDA warning that turns the stock into a pure regulat…
Read analysis →